The Case Against (and for) Donald Berwick
Throughout his lengthy career Berwick has made a lot of comments and some of them are coming back to haunt him. According to his critics, Berwick is a radical proponent of healthcare rationing, so-called “death panels” and the British system of healthcare.
- Why he should stay: Healthcare is too important to allow the level of discourse to fall so low.
- Why he should go: In the era of the 24-hour news cycle, Berwick makes great theater. The soundbite rules so his speeches and writings are mined for controversy. Yes, the statements are often used out of context but as long as Berwick remains the nominee it will be hard for the healthcare reform debate to move beyond emotion-laden words like “rationing” and “death panels.”
Don Berwick is a Harvard-educated pediatrician who has spent much of his career as a policy analyst. HealthLeaders Media wrote about him last year: "Berwick's record as a healthcare shepherd is unassailable. Through the Institute for Healthcare Improvement he founded, Berwick and his team cleverly hooked into the healthcare industry's untapped desire to improve with catchy, actionable programs like the 100,000 Lives Campaign. His critics worry that at CMS, what Berwick envisions would be less like feel-good voluntary programs and more toward British-style universal care of which he has spoken fondly."
- Why he should stay: His specialty is examining how a healthcare system can improve patient care while holding down costs. That is exactly what everyone says should happen.
- Why he should go: One ongoing criticism of Berwick is that he lacks experience in management and with health plans.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Top-Ranked MA Plans Earn Their Stars
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening